ArticleHealth affairs (Project Hope)2013
A call for evidence-based medical treatment of opioid dependence in the United States and Canada.
Article in Health affairs (Project Hope), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Short term health-related quality of life improvement during opioid agonist treatment.Drug and alcohol dependence · 2015Pooled it
- Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.Journal of substance abuse treatment · 2015Pooled it
- Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.Addiction (Abingdon, England) · 2022Trial
- Baseline characteristics of patients predicting suitability for rapid naltrexone induction.The American journal on addictions · 2015Trial
- HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.Journal of acquired immune deficiency syndromes (1999) · 2014Trial
- Contributions of a central registry to monitor methadone -treatment through the HEALing Communities Study.Journal of opioid management · 2023Article
- Outcomes of State Targeted/Opioid Response Grants and the Medication First Approach: Evidence of Racial Inequities in Improved Treatment Access and Retention.Substance abuse · 2023Article
- Article
- Article
- Guiding officers to deflect citizens to treatment: an examination of police department policies in Illinois.Health & justice · 2023Article
- Variation in Clinical Characteristics and Longitudinal Outcomes in Individuals with Opioid Use Disorder Diagnosis Codes.Journal of general internal medicine · 2023Observational
- Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX.Journal of substance abuse treatment · 2022Article
- Changes in methadone take-home dosing before and after COVID-19.Journal of substance abuse treatment · 2022Article
- Predictors of Retention and Drug Use Among Patients With Opioid Use Disorder Transferred to a Specialty "Second Chance" Methadone Program.Substance abuse : research and treatment · 2022Article
- Prevalence of lifetime nonmedical opioid use among U.S. Health Center Patients aged 45 years and older with psychiatric disorders.Aging & mental health · 2022Article
- Article
- Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse.Drug and alcohol dependence · 2021Article
- In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.Biological psychiatry · 2020Article
- Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.Journal of substance abuse treatment · 2020Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
Despite decades of experience treating heroin or prescription opioid dependence with methadone or buprenorphine--two forms of opioid substitution therapy--gaps remain between current practices and evidence-based standards in both Canada and the United States. This is largely because of regulatory constraints and pervasive suboptimal clinical practices. Fewer than 10 percent of all people dependent on opioids in the United States are receiving substitution treatment, although the proportion may increase with expanded health insurance coverage as a result of the Affordable Care Act. In light of the accumulated evidence, we recommend eliminating restrictions on office-based methadone prescribing in the United States; reducing financial barriers to treatment, such as varying levels of copayment in Canada and the United States; reducing reliance on less effective and potentially unsafe opioid detoxification; and evaluating and creating mechanisms to integrate emerging treatments. Taking these steps can greatly reduce the harms of opioid dependence by maximizing the individual and public health benefits of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.